SAN DIEGO, Aug. 12 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the publication of a second study conducted on its proprietary compound, 1-TDC, for the treatment of periodontal disease. Dr. Hatice Hasturk, D.D.S., Ph.D. from Boston University, Department of Periodontology and Oral Biology, led the investigative team. The study was [...]

{ Comments on this entry are closed }

SAN DIEGO, March 19 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today that Director of Research and Development, Dr. Robert Hesslink, presented basic research outlining the cellular pathway instrumental in the efficacy of Celadrin®. Dr. Hesslink outlined the pathway before an audience of scientists and industry leaders at the Nutrigenomics 2008 [...]

{ Comments on this entry are closed }

SAN DIEGO, Feb. 25 /PRNewswire/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today that the International Federation of Sports Medicine (FIMS) and its Executive Committee has selected Celadrin® Topical Cream as its Official Pain Relieving Cream. FIMS’s goal since 1928 was to provide the best medical care for the athletes of the [...]

{ Comments on this entry are closed }

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the appointment of Dr. Thomas Van Dyke to its Medical Advisory Board. Dr. Van Dyke will provide guidance to Imagenetix on their experimental compound, 1-TDC, for the treatment and prevention of periodontal disease. Dr. Van Dyke is Professor, Department [...]

{ Comments on this entry are closed }

Expects To See Substantial Sales Growth Balance of Year SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), will present at the Noble Financial Equity Conference at 11:30 a.m. EDT on Tuesday, August 21, 2007 at the Charleston Place Hotel in Charleston, South Carolina. William Spencer, Imagenetix’s Chief Executive Officer [...]

{ Comments on this entry are closed }